Get the Stockscreener App
70.18
0.43%
-0.30
After Hours:
70.18
Disc Medicine Inc stock is traded at $70.18, with a volume of 300.16K.
It is down -0.43% in the last 24 hours and up +16.89% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$70.48
Open:
$70.6
24h Volume:
300.16K
Relative Volume:
0.44
Market Cap:
$2.68B
Revenue:
-
Net Income/Loss:
$-212.18M
P/E Ratio:
-11.72
EPS:
-5.9897
Net Cash Flow:
$-181.33M
1W Performance:
+5.90%
1M Performance:
+16.89%
6M Performance:
-8.83%
1Y Performance:
+69.89%
1-Day Range:
$69.70
$70.96
1-Week Range:
$65.46
$70.96
52-Week Range:
$39.20
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
70.18 | 2.69B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
IRON (NASDAQ: IRON) affiliate files Form 144, reports planned sale of 5,731 shares - Stock Titan
Panic Selling: Whats Disc Medicine Incs historical returnQuarterly Earnings Summary & Real-Time Buy Signal Notifications - baoquankhu1.vn
Volume Recap: Can Disc Medicine Inc outperform in the next rally2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Pullback Watch: Whats the beta of Disc Medicine Inc stock2026 Market Sentiment & Weekly Return Optimization Plans - baoquankhu1.vn
Behavioral Patterns of IRON and Institutional Flows - Stock Traders Daily
Press releases provided by CNW - Techaeris
Gainers Report: Whats Disc Medicine Incs historical return2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
Disc Medicine Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - FinancialContent
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Bluefield Daily Telegraph
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
Volatility Watch: Is Disc Medicine Inc stock good for income investors2026 Geopolitical Influence & Safe Entry Zone Identification - baoquankhu1.vn
Aberdeen Group plc Purchases 202,297 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Sees Relative Strength Rating Improve To 73 - Investor's Business Daily
Disc Medicine (IRON) Is Up 7.2% After Advancing Bitopertin Phase 3 Despite FDA Efficacy Concerns - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Shareholders to Connect - ACCESS Newswire
Assessing Disc Medicine (IRON) Valuation After FDA Complete Response Letter And Shareholder Investigation - Sahm
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Shareholders to Connect | NDAQ:IRON | Press Release - Stockhouse
Retail Trends: Should I invest in Disc Medicine Inc before earnings2026 Key Lessons & Risk Controlled Swing Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out - ACCESS Newswire
ROSEN Law Firm Encourages Disc Medicine Investors - National Today
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, - GlobeNewswire
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out | NDAQ:IRON | Press Release - Stockhouse
ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Shareholders to Learn More About the Investigation | NDAQ:IRON | Press Release - Stockhouse
Insider Buy: Will Disc Medicine Inc outperform during market rallies2026 Earnings & Low Volatility Stock Recommendations - baoquankhu1.vn
IRON Investors Lose Up to $22/Share -- LEVI & KORSINSKY, LLP Investigates Disc Medicine - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-03-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Investors to Learn More About the Investigation | NDAQ:IRON | Press Release - Stockhouse
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
(IRON) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Stifel reiterates Disc Medicine stock rating after rival drug data By Investing.com - au.investing.com
Stifel reiterates Disc Medicine stock rating after rival drug data - Investing.com
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Disc Medicine, Inc. (IRON) - TMX Newsfile
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - ACCESS Newswire
Expanded Phase 3 APOLLO Enrollment for Bitopertin in EPP/XLP Might Change The Case For Investing In Disc Medicine (IRON) - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
2026-03-27 | Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Stockholders to Inquire about Securities Investigation | NDAQ:IRON | Press Release - Stockhouse
Disc Medicine, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Disc Medicine completes enrollment in bitopertin EPP trial By Investing.com - Investing.com Australia
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - The Manila Times
Published on: 2026-03-27 10:30:49 - baoquankhu1.vn
Disc Medicine completes enrollment in bitopertin EPP trial - Investing.com
Disc Medicine announces completion of enrollment of phase 3 Apollo trial of bitopertin in erythropoietic protoporphyria - marketscreener.com
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):